ADMA Biologics
ADMA
72 hedge funds and large institutions have $47.3M invested in ADMA Biologics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 24 closing their positions.
0.86% less ownership
Funds ownership: 33.46% → 32.6% (-0.86%)
20% less funds holding
Funds holding: 90 → 72 (-18)
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
30% less capital invested
Capital invested by funds: $67.7M → $47.3M (-$20.4M)
75% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 24
78% less call options, than puts
Call options by funds: $473K | Put options by funds: $2.14M
Top Buyers
| 1 |
BFM
Boothbay Fund Management
New York
|
+$4.07M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.37M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$776K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$364K |
| 5 |
Morgan Stanley
New York
|
+$305K |
Top Sellers
| 1 |
PA
Perceptive Advisors
New York
|
-$4.65M |
| 2 |
Millennium Management
New York
|
-$589K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$513K |
| 4 |
E
Ergoteles
New York
|
-$479K |
| 5 |
Barclays
London,
United Kingdom
|
-$461K |
ADMA Hedge Fund Activity: Q3 2021 in Review
72 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q3 2021, worth a combined $47.3M — down 30% from $67.7M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ADMA and 6 opened new positions — a net loss of 18 holders — while 26 trimmed existing stakes and 19 added.
The largest buyer was Boothbay Fund Management, adding an estimated $4.07M. The largest seller was Perceptive Advisors, cutting an estimated $4.65M.
- 72 institutional investors held ADMA Biologics (ADMA) as of Q3 2021, down from 90 in Q2 2021.
- Funds reported $47.3M of ADMA Biologics stock for Q3 2021, down 30% quarter-over-quarter.
- 6 funds opened new ADMA Biologics positions in Q3 2021 and 24 closed out, a net change of -18 holders.
- The largest ADMA Biologics buyer in Q3 2021 was Boothbay Fund Management, an estimated $4.07M added.
- The largest ADMA Biologics seller in Q3 2021 was Perceptive Advisors, an estimated $4.65M sold.
Based on aggregated 13F filings for Q3 2021.